Industry News

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• TLC BioSciences Reports Positive Phase 3 Topline Results for TLC590 in Bunionectomy Pain: Reported by Orthopedics This Week, TLC BioSciences announced that its pivotal Phase 3 trial of 304 patients demonstrated that extended-release ropivacaine (TLC590) achieved statistically significant reductions in pain intensity with movement through 72 hours (p=0.0024) and rescue opioid consumption through 168 hours compared with both placebo and active comparator liposomal bupivacaine.
• FibroBiologics Unveils Preclinical Disc Regeneration Data at NASS 2026: Reported by OrthoSpineNews, FibroBiologics presented preclinical data demonstrating that its allogeneic fibroblast spheroid-derived chondrocyte (FSdC) cell therapy significantly preserved normalized disc height index at 80.7% versus 71.8% in controls over 12 weeks (p<0.05) in intervertebral disc degeneration.
• Armònia SGR Acquires Orthopaedic Implant CDMO HPF to Accelerate International Expansion: Reported by BONEZONE, Italian private equity firm Armònia SGR acquired the entire share capital of HPF, an orthopaedic forging and precision machining CDMO serving hip, knee, and spine OEM device manufacturers, to scale production capacity and international acquisitions.
• Zimmer Receives 510(k) Clearance for OsseoFit Stemless Shoulder System: Zimmer, Inc. received FDA 510(k) clearance (K262955) for the OsseoFit Stemless Shoulder System indicated for uncemented anatomic total shoulder arthroplasty with metaphyseal humeral fixation avoiding diaphyseal canal preparation.
• Arthrex Secures 510(k) Clearance for Arthrex Beaming System: Arthrex, Inc. obtained FDA 510(k) clearance (K262975) for the Arthrex Beaming System indicated for bone fracture fixation, arthrodesis, osteotomy, and reconstruction across orthopaedic trauma and extremities.

DAILY ANNOUNCEMENTS BY CATEGORY

Trauma & Extremities

TLC BioSciences Corp.: TLC BioSciences Announces Positive Topline Phase 3 Results for TLC590 Extended-Release Ropivacaine in Postsurgical Bunionectomy Pain

• Summary: TLC BioSciences Corp. announced positive topline results from its randomized, double-blind, active- and placebo-controlled pivotal Phase 3 trial evaluating TLC590, an investigational extended-release ropivacaine formulation, in 304 patients undergoing bunionectomy. The trial met its primary efficacy endpoint, demonstrating statistically significant reductions in cumulative pain intensity with movement through 72 hours compared with placebo (p=0.0024), alongside significantly decreased total rescue opioid consumption (p=0.0109). In head-to-head active comparator evaluations against liposomal bupivacaine, TLC590 demonstrated statistically significant superiority in pain reduction through 72 hours (p=0.0202) and rescue opioid reduction (p=0.0177), with analgesic durability sustained through 168 hours (p=0.0226) and no drug-related serious adverse events reported.
• Key Details:
  • Device/System Name: TLC590 Extended-Release Ropivacaine
  • Status: Pivotal Phase 3 Clinical Trial Topline Data Announced (NDA Submission in Preparation)
  • Clinical Significance: Delivers durable, single-dose non-opioid local analgesia extending through 7 days (168 hours) postoperatively, establishing clinical superiority over current standard-of-care liposomal bupivacaine while significantly curbing postsurgical opioid requirements in foot and ankle surgery.
• Original Source: Orthopedics This Week

Spine & Orthobiologics

FibroBiologics, Inc.: FibroBiologics Presents Preclinical Data on Spheroid-Derived Chondrocyte Cell Therapy for Degenerative Disc Disease at NASS 2026

• Summary: At the North American Spine Society (NASS 2026) Annual Meeting, FibroBiologics, Inc. presented preclinical findings (Abstract #152) evaluating allogeneic human fibroblast spheroid-derived chondrocytes (FSdC) in an established rabbit model of degenerative disc disease. Investigators compared conventionally cultured 2D fibroblasts, 3D fibroblast spheroids, and FSdC spheroids following a single intradiscal injection over a 12-week evaluation period with X-ray, MRI, and histological analysis. FSdC spheroids demonstrated robust chondrogenic differentiation via positive Alcian blue staining and upregulation of cartilage genes (COMP, SOX9, and ACAN), maintaining statistically superior normalized percent disc height index values (80.7% vs. 71.8% in controls; p<0.05) throughout the 12-week study across all lumbar levels evaluated.
• Key Details:
  • Device/System Name: Fibroblast Spheroid-Derived Chondrocyte (FSdC) Spheroid Cell Therapy
  • Status: Preclinical Study Results Presented at NASS 2026 (Abstract #152)
  • Clinical Significance: Offers a potential biologic regenerative strategy to restore functional disc matrix and arrest intervertebral disc degeneration without surgical fusion, delivering allogeneic cartilage-forming cells directly into the degenerated disc space.
• Original Source: OrthoSpineNews

Corporate, M&A & Regulatory

Armònia SGR / HPF S.r.l.: Italian Private Equity Firm Armònia SGR Acquires Orthopaedic Implant CDMO HPF

• Summary: Italian private equity firm Armònia SGR, on behalf of its Armònia Italy Fund II, completed the acquisition of the entire share capital of HPF S.r.l. from Gradiente SGR, Amil S.r.l. (holding company of the Lualdi family), and Nord Holding. Founded in 2007 in Forgaria nel Friuli, Italy, HPF operates as a contract development and manufacturing organization (CDMO) specializing in hot forging and precision machining of orthopaedic implants and surgical instrumentation for hip, knee, and spine systems. Under the continued leadership of CEO Marco Pirisi, HPF has expanded revenue by approximately 10% annually since 2022, reaching just under 30 million euros (approximately 34 million US dollars) in 2025 across all industrial segments.
• Key Details:
  • Device/System Name: Orthopaedic Hot Forging & Precision Machining CDMO Platform
  • Status: M&A Transaction Completed (Entire Share Capital Acquisition)
  • Clinical Significance: Enhances supply chain resilience and manufacturing capacity for major orthopaedic reconstructive and spinal OEMs through advanced European forging and precision machining capabilities.
• Original Source: BONEZONE

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES: ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2 to 4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.